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Multiple sclerosis (MS) is a progressive neurodegenerative disorder that affects 140 out 
of every 100,000 individuals in North America. MS is believed to be mediated by T cells, in 
which the T cells directly attack or indirectly activate immune cells for attack on the myelin 
sheath of neurons, which can lead to blindness, paralysis, muscle weakness, and walking 
difficulties. Treatment of MS involves the use of immunomodulatory therapeutics, such as 
interferon-β (IFN-β), to decrease the progression of demyelination within the CNS. IFN-β has 
been linked to many different immunomodulatory roles in the pathology of MS. Of interest, IFN-
β is believed to alter T-cell activation, cytokine production, and transmigration of immune cells. 
Studies have found that IFN-β increases co-stimulatory molecule production in dendritic cells 
and monocytes. IFN-β has also been found to alter various cytokine expressions within immune 
cells, such as T-cells and dendritic cells. In addition, IFN-β inhibits immune cell movement 
through the blood-brain barrier. These results taken together suggest a complex inhibitory 
system, propagated by IFN-β signaling, that may reduce the functionality of T cells and dendritic 
















 Multiple sclerosis (MS) is a progressive neurodegenerative, autoimmune disease where 
an individual’s immune system attacks the central nervous system (CNS), which may lead to 
muscle weakness, trouble swallowing, depression, blindness, and paralysis (Parham, 2015; 
National Multiple Sclerosis Society, 2018). MS affects 33 out of every 100,000 individuals 
worldwide, with greater prevalence in North America (Leray et al., 2016).  
The symptoms of MS result from the demyelination of the axons of specialized cells of 
the central nervous system called neurons (Marieb et al., 2016). Neurons have a unique structure 
in which an axon extends from the cell body of the neuron and connects each neuron allowing 
for electrical signals to be sent through the nervous system (Marieb et al., 2016). The axon is 
surrounded by myelin which functions as an insulator for the axons (Marieb et al., 2016). Myelin 
is crucial for the fast transduction of the electrical signals down the axons of the neurons (Marieb 
et al., 2016). Demyelination is believed to be mediated by T cells. The T cells directly attack or 
activate immune cells for attack on the myelin of neurons (Garg et al., 2015). In the 
immunopathology of MS, there are three distinct phases in the process of demyelination: 1) 
activation and differentiation of T cells; 2) transmigration of immune cells; and 3) immune 
response to neurons of the CNS (Garg et al., 2015). This immunopathology is believed to prime 
T cells for distinct roles in the demyelination of neurons, such that the immune cells move to the 
CNS and enact distinct inflammatory and immune responses against the host’s myelin (Garg et 
al., 2015). 
 The current treatments available for MS are not cures, but rather aim at reducing the 
progression of the disease. Many different therapeutics exist for the treatment of MS, including 
glatiramer acetate, teriflunomide, fingolimod, alemtuzumab, and ocrelizumab (National Multiple 
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Sclerosis Society, 2018). The most common treatment for MS prescribed is interferon-β. 
Interferon-β (IFN-β) is a protein made within the human body and synthetically that enacts many 
changes to the immune cells through cell signaling (Parham, 2015). Within the immune system, 
IFN-β acts by reducing viral infection (Parham, 2015). However, treatments with IFN-β to some 
individuals with MS have shown marked decreases to the progression of the disease (Rog et al., 
2006). Studies have shown that treatment with IFN-β to individuals with MS leads to many 
different changes in the function of immune cells, especially T cells and dendritic cells, which 
may alter the progression of MS. Three areas of effect were studied within this review: 1) the 
effect of IFN-β on T cell activation; 2) the effect of IFN-β on T cell and dendritic cell cytokine 
production; and 3) IFN-β effect on immune cell transmigration.  
 In this review, inhibitory and regulatory effects of IFN-β will be discussed. The 
inhibitory and regulatory effects of IFN-β include the changes to cytokine expression in dendritic 
and T cells, the effect of IFN-β on costimulatory and coinhibitory molecules in T cells and 
dendritic cells, and the inhibition of immune cell movement. The analysis of the data of current 
studies can provide new insights into the function of IFN-β as a therapeutic and its effect on 
immune cells. These findings can reveal new hypotheses into the immunopathology of MS. 
Additionally, these studies’ findings can show new insights into the effects of IFN-β treatment in 
MS patients.  
 
Epidemiology and Etiology of MS: 
The prevalence of MS in the world has been increasing over the years from 30/100,000 
individuals in 2008 to 33/100,000 individuals in 2013 (Leray et al., 2016). However, in North 
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America, the prevalence is the highest with 140 individuals per every 100,000 individuals being 
affected by the disease (Leray et al., 2016). In addition, the prevalence of MS is higher in women 
than in men with the peak onset of the disease appearing between twenty and fifty-five years old 
(Garg and Smith, 2015). Roughly 2.5 million individuals are affected by the disease worldwide. 
About eight-five percent of these individuals have relapsing-remitting multiple sclerosis, which 
is a period of new symptoms (relapse) that are followed by remissions with no new symptoms 
occurring (stable state) (National MS Society, 2018). The individuals diagnosed with relapsing-
remitting MS will eventually progress to secondary progressive MS, which is a period of 
progressive decrease to an individual’s neurological functioning (National MS Society, 2018).  
The causative factors of MS have not been completely elucidated. Many different 
hypotheses exist to explain the onset of MS, such as exposure to smoking in childhood, reduced 
vitamin D throughout life, and exposure to Epstein-Barr virus in childhood (Leray et al., 2016; 
Tullman, 2013). These factors have all been correlated to the increased incidence of MS (Leray 
et al., 2016; Tullman, 2013). In addition, these potential environmental causative factors 
occurred primarily in childhood (Leray et al., 2016). Interestingly, MS may have a strong genetic 
component in addition to the environmental components. This genetic component can be seen in 
the ratio of women affected by MS in comparison to men. It has been shown that MS affects 
about 3 women to every 1 man, suggesting a sex linkage to the incidence of MS (Harbo et al., 
2013). Additionally, it has been found that the risk of MS increases the more immediate the 
familial connection, such that daughter of the mother may have a higher risk of MS than the 
cousin of the mother (Kantarci, 2008). This hereditary aspect of MS may be due to certain 
genetic components, such as the expression of human leukocyte antigen-DR15 (HLA-DR15) 
haplotype (Leray et al., 2016). HLA-DR15 is a molecule on the surface of antigen-presenting 
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cells that holds foreign peptide fragments for T cells to react (Scholz et al., 2017). It is suggested 
that the distinct phenotype of the HLA-DR15 haplotype may predispose individuals for MS 
because it can present autoantigens for the attack on the central nervous system (Scholz et al., 
2017).    
Interferon-β: Signaling Pathway and Relevance: 
One of the most common therapeutics used in treatment for MS is interferon-β (IFN-β) 
(Figure 1). IFN-β is therapeutic that diminishes the effects of MS and reduces the progression of 
MS, but does not cure the disease. Studies show that IFN- β caused a 30% decrease in the relapse 
rate of patients and the decrease of new lesions formed within the brain (Rog and Mottershead, 
2006). IFN-β is a protein that binds to receptors found within many different immune cells called 
interferon-alpha/β receptors (IFNARs) (Weerd and Nguyen, 2012). The effects of IFN-β are 
widespread because the interferon-β receptors have been isolated on many different immune cell 
surfaces, such as T cells, dendritic cells, and macrophages (Weerd and Nguyen, 2012). The 
normal function of IFN-β in the host immune system is to induce viral protection within cells 
(Parham, 2015). Interestingly, in the treatment of MS, the binding of IFN-β to its specific 
receptors on various immune cells can cause many changes to the immune cells, which may limit 
the immune cells’ abilities to enact immune responses to the autoantigens within the host’s 
central nervous system. Some of these inhibitory functions enacted by IFN-β signaling are the 
changes to cytokines present within the environment of the T cell, the inhibition of T cell 
activation, and the inhibition to immune cell movement.  
 These alterations to the behaviors of various immune cells is mediated through a specific 
intracellular pathway (Figure 2). IFN-β binds to interferon alpha/β receptors (IFNAR) present on 
many different immune cells, including T cell subtypes, macrophages, and antigen-presenting 
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dendritic cells. Upon binding to the IFNAR-1 or -2, IFNAR-1 and -2 complex form a dimer. The 
dimerization of IFNAR-1 and -2 leads to the auto-phosphorylation of associated kinases: Janus 
and tyrosine kinases (Ivashkiv et al., 2014). Janus-activated kinase-1 (JAK-1) is associated with 
IFNAR-2, and tyrosine kinase-2 (TYK-2) is associated with IFNAR1. Autophosphorylation of 
IFNAR-1 and -2 leads to the formation of docking sites on the receptors (Ivashkiv et al., 2014). 
These docking sites bind signal transducers and activators of transcription (STATs) (Ivashkiv et 
al., 2014). Activated STAT proteins can dimerize and complex with other proteins to form 
specific transcriptional modifying protein complexes (Ivashkiv et al., 2014). Of interest to IFN-β, 
JAK-1 and TYK-2 allow for the phosphorylation and activation of STAT-1 and STAT-2 
(Ivashkiv et al., 2014). The activated STATs can dimerize to form either homodimers or 
heterodimers. Any STAT complex can translocate to the nucleus and induce modifications to 
transcription. IFN-β signaling can lead to the formation of a complex called the interferon 
stimulated gene factor 3 (ISGF3) (Ivashkiv et al., 2014). ISGF3 is formed by the complexing of 
STAT-1 and STAT-2 with a DNA binding protein, interferon regulatory factor 9 (IRF9) 
(Ivashkiv et al., 2014). Once the dimers and complexes form and travel to the nucleus, different 
actions occur. For example, the STAT1 homodimer can bind to the IFN-y-activated sequences 
(GAS), whereas the ISGF3 complex can bind to the IFN-stimulated response elements (ISREs) 
(Ivashkiv et al., 2014). Each of these DNA binding and transcriptional changes leads to different 
gene expression performed by the cells that has been correlated to reduced inflammatory 
response (Ivashkiv, et al., 2014). Thus, it is possible that the transcriptional changes occurring 
from the IFN-β signaling lead to the positive results found in some individuals with MS that use 




 The Nervous System and Its Relation to MS: 
The nervous system is the network of communication and control found within the body. 
The nervous system performs three functions: 1) sensory input, 2) integration of the sensory 
input, 3) motor output (Marieb et al.,2016). The CNS controls all of the integration of the 
sensory information received from neurons all over the body and produces an output to react to 
the sensory information (Marieb et al.,2016). Within MS pathology, the immune system attacks 
the neurons of the central nervous system (CNS), which comprises the brain and the spinal cord 
(Archelos et al., 2002).  
Neurons have a unique structure (Figure 3). The neuron contains a cell body, which holds 
the nucleus for the cell. The cell body has many projecting branches called dendrites that receive 
signals from other neurons, allowing for the propagation of signals from one neuron to the next 
(Marieb et al., 2016). The neuron also contains a single axon that carries a signal to the next 
neuron (Marieb et al., 2016). The transduction of the signals from one neuron to the next occurs 
at the synapse (Marieb et al., 2016). The synapse is a microscopic gap between the axon of the 
neuron sending the signal and the dendrite of the neuron receiving the signal (Marieb et al., 
2016). The signal is propagated from one neuron to the next by way of chemical signal. The 
transduction of electrical signal by the signal-sending neuron causes a release of chemicals 
across the synaptic gap (Marieb et al., 2016). These chemicals bind to corresponding receptors 
on the dendrite of the receiving neuron leading to a change in ion flux producing an electrical 
signal in the signal receiving neuron (Marieb et al., 2016). 
The fast transduction of the electrical signal down an axon is essential for the healthy 
function of any human nervous system. This fast transduction can only occur with the assistance 
of an insulator around the axon. This insulator is called myelin (Marieb et al., 2016). Myelin is a 
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sheath that surrounds the exterior of the axon (Marieb et al., 2016). It consists of layers of 
proteins and lipids (Morell et al., 1999). Connected to the myelin in the CNS is an 
oligodendrocyte. An oligodendrocyte is a myelin-producing cell, which both repairs and restores 
the myelin sheath, thus producing both proteins and lipids that wrap around the axon (Salzer et 
al., 2016). These layers of protein and lipids function as insulators to the electrical signal being 
sent down the axon (Marieb et al., 2016). If the insulation was not present, the electrical signal 
would dissipate before reaching its target neuron, or the body would have to expend more energy 
in order to propagate the neuronal signal from one neuron to the next (Marieb et al., 2016).  
Two proteins have been found within myelin that have a linkage to MS pathology. 
Myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) have been used to 
induce auto-reaction for myelin within the immune cells of patients with MS (Peschl et al., 2017; 
Beniac et al., 1997). Consequently, immune cells can be activated for attack on the myelin 
proteins, thus disrupting and degrading the structure of the myelin sheath (Archelos et al., 2002). 
Without the myelin sheath, the electrical signals may be carried from one neuron to the next 
because the signal will dissipate before reaching the next neuron (Marieb et al., 2016). In the 
case of MS, this loss of rapid signaling, and possible loss of signaling in general, can lead to 
paralysis or blindness, as well as muscle weakness and loss of sensation (National Multiple 
Sclerosis Society, 2018).     
 
The Immune System and Its Role in MS: 
 MS is an autoimmune disease in which the immune system causes demyelination of the 
CNS.  Many different parts of the immune system play a role in the immunopathogenesis of MS. 
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Thus, it is important to discuss the different cells that play a role in the immunopathogenesis of 
MS. The immune system consists of the lymphatic system that is a series of vessels carrying 
immune cells to and from the blood stream (Parham, 2015). The lymphatic system connects the 
lymphoid tissues, which hold or produce a majority of the immune cells, to the blood stream 
(Parham, 2015). The peripheral lymphatic tissues are the areas where the lymphocytes, such as T 
cells, are primed for a response against a specific antigen (Parham, 2015). Antigens are foreign 
proteins that are found on pathogens, such as viruses or bacteria, and are taken up by 
phagocytosis and presented to T cells on antigen-presenting cells (Parham, 2015; Goldsby et al., 
2002). In the case of MS, the antigen presented on antigen-presenting cells is an auto-antigen. 
Auto-antigens are proteins derived from the cells of the host, such as MBP or MOG from myelin 
(Parham, 2015).  
The process of priming T cells involves two types of cells: CD4+ T cells and antigen-
presenting cells (Parham, 2015; Goldsby et al., 2002). T have various functions (Parham, 2015; 
Goldsby et al., 2002). For example, CD4+ T cells are a distinct type of T cell because they 
express the CD4 T cell receptor on their cell surfaces (Parham, 2015). When these cells are 
activated, they function by activating other immune cells and producing cytokine environments, 
inducing a specific immune response to the antigen (Parham, 2015; Goldsby et al., 2002). The 
CD4+ T cell associates with antigen-presenting cells, such as monocytes and dendritic cells. 
Monocytes are cells that are present within the blood, spleen, and bone marrow, but cannot 
proliferate (Geissman et al., 2010). These cells are unique because they can differentiate into 
dendritic cells (DCs) (Geismann et al., 2010). Dendritic cells are the main antigen-presenting 
arm of the immune system (Geissman et al., 2010). DCs are far more potent at activating T cells 
and are differentiated from monocytes via the cytokine environment present, such that if enough 
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of a specific cytokine signal enters the cell, then the monocyte will begin to differentiate into a 
dendritic cell (Geissman et al., 2010). Dendritic cells travel throughout the bloodstream and 
tissues, phagocytosing foreign molecules and presenting them on MHC molecules for T cell 
activation (Geissman et al., 2010). 
Once primed by the antigen-presenting cells (DCs and monocytes), the primed CD4+ T 
cells are differentiated by cytokine signaling (Parham, 2015). Cytokines are proteins produced by 
immune cells, such as macrophages, T cells, and antigen-presenting cells (Parham, 2015; 
Goldsby et al., 2002). The cytokine signal induces transcriptional changes within primed CD4+ 
T cells, leading to distinct functional roles depending on the transcriptional factor present 
(Parham, 2015; Goldsby et al., 2002). Two effector CD4+ T cells play a role in the 
immunopathology of MS: T helper type 1 (TH1) cells and T helper type 17 (TH17) cells. TH1 
cells are distinct because they express the transcriptional factor T-bet (Parham, 2015; Goldsby et 
al., 2002). The T-bet expression in primed CD4+ T cells is in response to the cytokine signaling 
from interleukin-12 (IL-12) and interferon-γ (IFN-γ). TH1 cells are believed to function by 
producing pro-inflammatory cytokines contributing to the inflammatory immune response 
(Parham, 2015; Goldsby et al., 2002). In addition, TH1 cells activate macrophages and produce 
cytokines that assist macrophages in their phagocytic roles (Parham, 2015; Goldsby et al., 2002). 
TH17 cells are distinct from TH1 cells because their transcription factor is RORγT (Parham, 
2015). The expression of RORγT in primed CD4+ T cell is induced by cytokine signaling of 
interleukin-6 (IL-6), interleukin-21 (IL-21), and tumor growth factor-β (TGF-β) (Parham, 2015; 
Martinez et al., 2008). TH17 cells are believed to function by producing pro-inflammatory 
cytokines that contribute to the inflammatory immune response (Parham, 2015; Martinez et al., 
2008). In addition, it has been shown that TH17 cells secrete the cytokines IL-17 A and IL-17 F 
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that have been found to increase neutrophil attraction and proliferation, as well as upregulating 
pro-inflammatory cytokines (Parham, 2015). This increase of neutrophils and pro-inflammatory 
cytokines can degrade epithelial barriers because of the phagocytic and inflammatory properties 
of neutrophils (Parham, 2015).  
These effector T cells can play a role in activating and inducing phagocytic cell function. 
Two phagocytic cells are linked to these effector T cells: macrophages and neutrophils. 
Macrophages are activated by TH1 cells (Parham, 2015). The macrophages receive two signals 
from the TH1 cells: interferon-γ (IFN-γ) signal and CD40 receptor signal (Parham, 2015; 
Goldsby et al., 2002). The activation of macrophages leads to the production of many pro-
inflammatory cytokines that increase the vascular permeability of endothelial cells, such as those 
found along the blood-brain barrier (Parham, 2015; Goldsby et al., 2002). In addition, these 
cytokines are also chemoattractants for other immune cells, signaling other immune cells to the 
site of attack (Parham, 2015; Goldsby et al., 2002). In the case of MS, the increase of pro-
inflammatory cytokines and chemoattractant cytokines leads to neuronal damage by 
inflammation (Parham, 2015). Neutrophils are one of the immune cells signaled by the cytokines 
released from macrophages and TH17 cells (Parham, 2015). Neutrophils are another subset of 
phagocytic cells that function by entering the site of infection and engulfing the pathogens and 
breaking them down (Parham, 2015; Goldsby et al., 2002). Neutrophils make up a majority of 
the white blood cells in the blood, and, as such, neutrophils are the first cells to the site of 
infection (Parham, 2015). In the case of MS, the increased vascular permeability may contribute 
to the increase of neutrophils in the CNS. Neutrophils could phagocytose the myelin in 
individuals with MS.   
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The roles of effector CD4+ T cells can also be suppressive. In the case of MS, regulatory 
T cells (Treg), a type of effector CD4+ T cell, may play a role in the suppression of autoreactive T 
cells, such as those cells primed for MOG or MBP. Treg cells are upregulated by the interaction 
of primed CD4+ T cells with interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) 
(Parham, 2015). The TGF-β and IL-10 signaling induce expression of the transcription factor 
FOXP3 (Parham, 2015). These Treg cells function by suppressing the proliferation and function 
of other effector CD4+ T cells, such as TH1 and TH17 (Parham, 2015). The process of inhibition 
is not yet fully understood. However, studies have shown that a distinct receptor, the cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4), decreases the expression of co-stimulatory 
molecules on antigen-presenting cells (Schmidt et al., 2012). Also, it was found that Treg cells 
produce perforin and granzymes that can induce apoptosis in effector T cells (Schmidt et al., 
2012).  In addition, these cells produce an anti-inflammatory cytokine environment that 
counteracts the pro-inflammatory cytokine environments produced by other effector CD4+ T 
cells (Parham, 2015). Most importantly, these cells dampen the activity of autoreactive T cells, 
such as those primed for MOG or MBP in MS, suggesting reduced autoimmune response with 
increasing Treg populations (Parham, 2015; Corthay, 2009; Danikowski et al., 2017).  
 
Immunopathogenesis of MS: 
The immunopathogenesis of MS involves the progression of demyelination and axonal 
damage of the neurons by the immune system (Archelos et al., 2003). The immunopathogenesis 
of MS is a process that occurs in three stages: 1) autoactivation, proliferation, and differentiation 
of T cells within the lymphoid tissues, 2) transmigration of immune cells across the blood-brain 
barrier (BBB) into the CNS, and 3) reactivation of T cells and targeted immune response within 
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the CNS, producing demyelination and axonal damage (Archelos et al., 2002; Garg et al., 2015) 
(Figure 4.).  
 
Autoactivation, Proliferation, and Differentiation of T cells in the Lymphoid Tissues: 
The immunopathogenesis of MS begins in the lymphoid tissues of the lymphatic system. 
The lymphoid tissues are connected to the bloodstream and skin and are tissues that allow the 
antigen-presenting cells (dendritic cells) to interact with lymphocytes and start the adaptive 
immune response (Parham, 2015; Garg and Smith, 2015). Critical to the adaptive immune 
response, which is a targeted immune response to a specific pathogen, are the T cells. T cells are 
lymphocytes of the immune system that form a specific targeted attack on the pathogen that they 
have been primed for (Parham, 2015). In the case of MS, the T cells are primed for the MBP and 
MOG in the CNS (Archelos et al., 2002). 
 In the immunopathology of MS, various types of effector CD4+ T cells have been 
implicated in the autoreactive immune response. The activation of any CD4+ T cell involves the 
interaction between the CD4+ T cell receptor and major histocompatibility (MHC) molecules 
presented on the dendritic cell and the interaction of the CD28 receptor and the B7 costimulatory 
molecule on the dendritic cell (Parham, 2015). The co-stimulation and T cell receptor 
interactions induce proliferation of the naïve T cells via the upregulation of multiple transcription 
factors (Parham, 2015) (Figure 5).  Differentiation of activated CD4+ T cells is believed to occur 
from signaling through cytokine receptor-cytokine interactions. Activated CD4+ T cells can be 
differentiated into various effect CD4+ T cell types by the interaction of cytokines, such as 
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interleukin-12 (IL-12), interferon-gamma (IFN-γ), interleukin-6 (IL-6), interleukin-21 (IL-21), 
and interleukin-17 (IL-17), with T cell receptors (Parham, 2015).  
Two effector CD4+ T cells play a role in the immunopathogenesis of MS: T helper type 1 
(TH1) cells and T helper type 17 (TH17) cells. TH1 cells function by producing inflammatory 
cytokines and inducing inflammatory responses near the site of infection, or near the myelin in 
the case of MS (Parham, 2015). Additionally, TH1 cells activate macrophages for attack (Parham, 
2015). In the case of MS, the macrophages can phagocytose parts of the myelin sheath and 
increase the inflammatory response on the myelin (Wolf et al., 1990).  TH17 cells play a role in 
the immunopathology of MS by inducing neutrophil attraction and neutrophil accumulation at a 
site of infection (Parham, 2015) (Figure 6).     
 
Transmigration of T Cells across the BBB: 
 Once the T cells are primed for their respective antigen, the T cells leave the lymphoid 
tissues and enter the bloodstream. The movement of the T cells through the blood brain barrier 
(BBB) occurs in the immunopathology of MS to allow for the T cells to begin an adaptive 
immune response to the autoantigens (MBP and MOG) found within the CNS. The process of 
transmigration (movement of T cells through the BBB) occurs with the T cell binding to the 
endothelial cells of the BBB by the interaction of various cell-adhesion molecules found on both 
the endothelial cells and T cells (Pinheiro et al., 2015). The interaction between the T cell and the 
endothelial cell via these molecules allows for the T cell to be slowed within the bloodstream and 
adhere to the endothelial cells (Pinheiro et al., 2015). The slowing of the T cells allows for 
increased reactions between these adhesion molecules, leading to the changes in the endothelial 
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cell connections called tight junctions (Pinheiro et al., 2015). The reduction in the connections 
between the endothelial cells allows the T cell to move through the gap (Pinheiro et al., 2015) 
(Figure 7). The final layer of the BBB is the basement membrane, which consists of many 
different structural proteins (Yong et al., 1998). The T cells produce matrix metalloproteinases 
(MMPs) that disrupt the basement membrane, allowing for degradation of the membrane (Yong 
et al., 1998). The degradation of the membrane allows for the T cells to enter into the CNS. 
 
Immune Response within the CNS: 
 Once within the CNS, the T cells can begin the adaptive immune response to the specific 
autoantigen for which they are primed for, which are the MBPs and MOGs. Lesions within the 
CNS for MS patients can be active or inactive (benign) (Lucchinetti et al., 2000). Lesions are 
areas of demyelination, such that there is scarring or degradation on a portion of the brain (Sethi 
et al., 2017) The difference between an active and an inactive lesion is the presence of 
demyelination (Lucchinetti et al., 2000). The presentation of demyelinating factors, such as pro-
inflammatory cytokines and increased levels of active T cells, shows that the lesion is active, and 
conversely, the lack of demyelinating factors shows that the lesion is inactive (Kornek et al., 
2000). Demyelination is a complex process within the immunopathology of MS that is not 
completely understood. It is speculated that the demyelinating process involves the activation of 
damaging immune cells, such as macrophages, by the CD4+ T cells primed for the MBPs or 
MOGs of the neurons (Archelos et al., 2002). This activation of immune cells causes the increase 
of inflammatory cytokines and the direct degradation of the myelin sheath in the CNS, increasing 
the extent of myelin damage and inflammation (Archelos et al., 2002). This direct degradation of 
Young 17 
 
the myelin occurs from the macrophages activated by T cells that have entered the CNS, 
engulfing the portions of the myelin containing the antigen (MBP and MOG) (Parham, 2015).  
 In addition to the TH1 activation of macrophages, TH17 cells are known to enact the 
recruitment and accumulation of neutrophils in the site of infection via IL-17 secretion (Parham, 
2015). Neutrophils, like all traveling immune cells, enter the infected tissue via the interaction of 
epithelial proteins and the movement along a chemokine gradient (Parham, 2015). Once inside 
the CNS, the neutrophil functions as a phagocytic cell (Parham, 2015). However, neutrophils 
possess greater variability in their phagocytosis, thus they may be able to degrade greater 
portions of myelin (Parham, 2015). The increase of both TH17 and TH1 cells can mediate a 
phagocytic attack on the myelin of the CNS, leading to lesion formation in MS patients. 
 
IFN-β’s Effect on T cell Activation: 
A key part of the immunopathology of MS is the activation of T cells for a specific 
autoantigen. For the activation of T cells, two signals are necessary. The first signal for the 
activation of T cells occurs between the T cell’s CD4 receptor and the major histocompatibility 
complex (MHC) molecule (Parham, 2015). MHC molecules function by displaying peptide 
fragments of antigens, which prime the T cell for attack on cells presenting the specific antigen 
(Parham, 2015). The second signal occurs between a CD28 receptor on the T cells and a 
costimulatory molecule (CD80, CD86, and CD40) present on dendritic cells (Goldsby et al., 
2002; Parham, 2015).  
In the case of MS, the results of many different studies’ findings regarding the 
upregulation of costimulatory and coinhibitory molecules by IFN-β treatment suggest a possible 
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inhibitory mechanism for T-cell activation. Namely, constant stimulation of T cells by the 
upregulated costimulatory molecules could lead to partial T cell exhaustion (Attanasio et al., 
2016). This T cell exhaustion leads to the upregulation of coinhibitory molecules on T cells 
(Attanasio et al., 2016; Carter et al., 2002). The signaling through the co-inhibitory molecules 
has been found to reduce the T cell proliferation and may induce apoptosis (Carter et al., 2002; 
Parham, 2015).  From these findings, it could be hypothesized that the amount of active T-cells 
would be reduced by the treatment of IFN-β to individuals with MS. This limitation to activation 
of T cells may reduce the ability of T cells to mediate active attacks and indirect attacks on the 
CNS. 
The treatment of monocytes with IFN-β was shown to increase the expression of CD80, 
CD86, CD40, and human leukocyte antigen-DR isotype (HLA-DR) both in vivo and in vitro 
(Wiesemann et al., 2008; Marckmann et al., 2004). Similar to the treatment of monocytes with 
IFN-β, dendritic cells have been shown to have increased expression of MHC I and II molecules, 
CD 80, CD86, and CD40 (Pennell et al., 2017). However, some discrepancy exists regarding the 
effect of IFN-β on costimulatory molecule expression. It has been found that the IFN-β treatment 
of DCs could lead to decreases in costimulatory molecules, such as CD40 and CD80 (McRae et 
al., 2000). In addition, McRae et al. show that there is diminished function by the dendritic cells 
to activate T cells when IFN-β is present (McRae et al., 2000). Interestingly, the controversial 
results of the effect of IFN-β may be due to the sample of dendritic cells and the donor used for 
the dendritic cells or monocytes. This discrepancy would yield varying results due to each cell’s 
complexity and variation in gene expression. These results suggest that the activation of T cells 
was increased by the upregulation of costimulatory molecules in monocytes and dendritic cells 
and MHC molecules in dendritic cells.  
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 The increase in costimulatory molecules conflicts with the therapeutic effects of IFN-β. 
However, IFN-β has also been found to increase coinhibitory molecules. Coinhibitory molecules 
are similar to costimulatory molecules, but they work in opposition. The coinhibitory pathway of 
interest involves programmed death 1 receptor (PD-1) and its ligands programmed death ligand 1 
and 2 (PD-L1, PD-L2) (Parham, 2015). These molecules have been implicated in cell signaling 
that causes cytokine alterations, increased differentiation of T cells into T regulatory cells, and 
reductions in cytotoxic T cells via apoptotic signaling, as well as apoptotic signaling in dendritic 
cells (Parham, 2015). For monocytes, IFN-β presence in cell culture showed increased levels of 
PD-L1 and PD-L2 in both healthy donors and MS patients (Wiesemann et al., 2008; Schreiner et 
al., 2004). PD-L1 and PD-L2 expression was not an exclusive case found in only one patient, but 
multiple MS patients had increased net expression of the PD-L1 co-inhibitory molecule 
(Wiesemann et al., 2008). However, the PD-L2 net expression did not increase to the same 
extent as PD-L1 (Wiesemann et al., 2008). In dendritic cells, only DCs semi-matured in 
inflammatory cytokine conditions and DCs matured in the presence of a superantigen 
(lipopolysaccharide) showed marked increases in PD-L1 when cultured in the presence of IFN-β 
(Schreiner et al., 2004; Wang et al., 2014). In addition to IFN-β treatment, it has been 
demonstrated that increased stimulation to CD4+ T cells by costimulatory molecules leads to the 
upregulation of PD-1 receptor on T cells (Carter et al., 2002). These results taken together 
suggest a possible inhibitory mechanism in which the overexpression of costimulatory molecules 
on dendritic cells and monocytes leads to overstimulation of CD4+T cells. This overstimulation 
could lead to an upregulation of PD-1 receptors on CD4+ T cells. Upregulation of PD-1 
receptors may lead to increased signaling through the PD-1, thus reducing the proliferation and 
activation of CD4+ T cells.  
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Effects of IFN-β on Dendritic Cell Cytokine Production: 
Cytokines play a key role in the differentiation of CD4+ T cells into their effector types 
(Parham, 2015). DCs can produce many different cytokines. DCs are one of the primary 
contributors to the cytokine milieu that determines the effector T cells differentiated (Parham, 
2015; Goldsby et al., 2002). IFN-β is known to alter the cytokine expression in DCs through the 
IFN-β signaling pathway. DCs are known to produce many different cytokines. Relevant to the 
immunopathology of MS, IFN-β has been shown to alter the expression of the following 
cytokines: interleukin-10 (IL-10), the interleukin-12 (IL-12) family, interleukin-6 (IL-6), and 
interferon-γ (IFN-γ). These alterations to cytokine expression could have various effects on the 
immunopathology of MS, such as the reduction in TH1 cell differentiation, an increase in T 
regulatory cell (Treg) differentiation, suppression of TH17 cells, and the decrease of macrophage 
functionality. These possible effects linked to the alterations of cytokine expression could reduce 
the demyelination and autoimmune response to myelin in individuals that have MS.  
 
IL-10 Expression in DCs and the Effect of IFN-β: 
 IFN-β treatment of DCs has been found to cause increases in the IL-10 expression in 
DCs. IL-10 has many different functions within the immune system. IL-10 is believed to be an 
anti-inflammatory cytokine. IL-10 is known, normally, to induce the differentiation of naïve T 
cells in to effector T regulatory cells (Treg) and T helper type 2 cells (TH2) (Hsu et al., 2015; 
Parham, 2015). In addition to increasing the expansion of Treg populations, IL-10 has been 
implicated in the downregulation of IL-12 in dendritic cells and macrophages (Goldsby et al., 
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2007). Thus, IL-10 production can lead to the inhibition of the activation of macrophages (O-
Farrell et al., 1998; Parham, 2015). In the case of MS, IL-10 may present a novel mechanism of 
inhibition for TH1 cell differentiation and macrophage function, such that TH1 cells and 
macrophages cannot affect an autoimmune response to myelin.     
 Dendritic cell expression of IL-10 can be regulated and altered by the treatment of IFN-β. 
In mice DCs lacking IFN-β expression, the production of IL-10 was significantly reduced in 
comparison to the mice with the normal IFN-β production (Pennell et al., 2017). This result 
suggests that the presence of physiological levels of IFN-β is necessary for production of normal 
levels of IL-10. In addition, it has been found that a marked increase in IL-10 expression has 
been seen in the exogenous treatment of DCs isolated from healthy human donors (Huang et al., 
2001). The IL-10 upregulation shown from the treatment of DCs with IFN-β is intriguing 
because the upregulation in DCs is not isolated to one location of the immune organs, such that 
bone marrow DCs, splenic DCs, lymph node DCs, and peripheral DCs are upregulating IL-10 
(Yen et al., 2015; Huang et al., 2001; Pennell et al., 2017). Interestingly, IL-10 upregulation by 
IFN-β treatment is shown to be caused by the IFN-β signaling pathway. It has been demonstrated 
that mice lacking interferon-α/β receptors (IFNARs) cannot produce increased levels of IL-10 
(Pennell et al., 2017; Yen et al., 2015). In addition, it has been found that one of the primary 
factors of IFN-β signaling the upregulation of IL-10 is the presence of signal transducer and 
activators of transcription 2 (STAT-2) (Yen et al., 2015). Thus, without STAT-2 expressed 
within mice, it was demonstrated that IFN-β had no effect on DC expression of IL-10 (Yen et al., 
2015). These results show that IFN-β treatment induces IL-10 expression through a JAK-STAT 
pathway in DCs throughout the lymphatic system.   
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  Upregulation of IL-10 could have many different positive effects within the 
immunopathology of MS. The expression of IL-10 has been shown to reduce pro-inflammatory 
cytokines, namely, IL-12 and IFN-γ (Huang et al., 2005, Yen et al., 2015). In addition, IL-10 is 
known to induce differentiation of primed CD4+ T cells to either TH2 cells or Treg cells (Hsu et 
al., 2015; Parham, 2015). These results may present a unique inhibitory mechanism. The down-
regulation of IL-12 and IFN-γ could reduce the differentiation of primed CD4+ T cells into TH1 
cells (Parham, 2015). Additionally, the presence of increased IL-10 in the cytokine milieu 
throughout the lymphatic system may play a role in the increased differentiation of primed CD4+ 
T cells into TH2 and Treg cells, thus reducing the TH1 cell population (Hsu et al., 2015; Parham, 
2015). Treg cells have also been found to regulate the autoreactive T cell populations by inducing 
apoptosis or rendering the autoreactive T cell anergic (Parham, 2015). TH1 cell differentiation 
being inhibited could decrease macrophage activation and the autoimmune response on myelin in 
individuals with MS (Parham, 2015; Goldsby et al., 2002). Additionally, the possible increased 
differentiation of Treg cells could reduce the number of autoreactive T cells, such as those primed 
for MOG or MBP, thus limiting the attack on myelin (Hsu et al., 2015).  
  
The Effect of IFN-β on the Cytokines of IL-12 Family: 
 DCs are known to produce many members of the IL-12 family, such as IL-12, IL-23, and 
IL-27, which can contribute to the differentiation of primed CD4+ T cells into TH1 cells (Nagai 
et al., 2003; Parham, 2015). IFN-β has been found to affect the expression of these cytokines. 
IFN-β has been shown to reduce the expression of IL-12 and IL-23 and increase the expression 
of IL-27 (Nagai et al., 2003; Yen et al., 2015; Huang et al., 2001; McRae et al., 2000). These 
three distinct cytokines have been implicated in the contribution to the increased differentiation 
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of CD4+ T cells: IL-12, IL-23, and IL-27 (Vignali et al., 2012). This differentiation of CD4+ T 
cells into TH1 cells by the mediation of IL-12 family cytokines could be linked to an increase in 
demyelination in patients with MS, and, thus, increase their symptoms. 
 The three distinct cytokines each have varying structures. The cytokines are heterodimers 
(Cooper et al., 2007; Vignali et al., 2012). For IL-12, the cytokine consists of two subunits: IL-12 
p35 and IL-12 p40 (Cooper et al., 2007). The IL-23 cytokine consists of the subunits IL-23 p19 
and IL-12 p40 (Cooper et al., 2007). IL-27 consists of two subunits: Epstein-Barr virus induced 3 
(EBI3) and IL-12 p 28 (Cooper et al., 2007). The varying structures of the IL-12 family members 
lead to different functions. IL-12 functions by upregulating IFN-γ expression in DCs and T cells 
(Cooper et al., 2007; Vignali et al., 2012). Both IL-12 and IFN-γ synergize to induce the 
differentiation of TH1 cells (Parham, 2015). The role of IL-23 is to steady the differentiation of 
primed CD4+ T cells into TH17 cells (Vignali et al., 2012). The IL-27 cytokine functions as a 
synergistic cytokine that, when in the presence of IL-2 and/or IL-12 induces IFN-γ production in 
T cells and increased proliferation of T cells (Vignali et al., 2012; Pflanz et al., 2002). In the 
immunopathology of MS, TH1 cells and TH17 cells may play a role in the demyelination of the 
CNS. Thus, the effects of the IL-12 family may increase the TH1 and TH17 differentiation and 
cell populations leading to greater demyelination.  
 IFN-β has been found to alter the IL-12 family cytokine expression in DCs. Many studies 
have shown that the treatment of DCs with IFN-β has led to the down-regulation of IL-12 p 40 
subunit (Yen et al., 2015; Huang et al., 2005; Huang et al., 2001; Nagai et al., 2003; McRae et 
al., 2000). In addition, it has been demonstrated that the treatment of DCs with IFN-β caused a 
decrease to the expression of IL-12 p35 subunit (Yen et al., 2015). Interestingly, the 
downregulation of the IL-12 p35 subunit was found in both the treatment of mice in vivo and the 
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in vitro treatment of mice DCs with IFN-β (Yen et al., 2015). These results show that the IL-12 
cytokine has limited expression when DCs are treated with IFN-β. This result could indicate 
reductions in IFN-γ production by various immune cells because IL-12 is known to be a catalyst 
for IFN-γ expression (Cooper et al., 2007; Vignali et al., 2012).  
 It is known that both the IL-12 cytokine and IL-23 cytokine share the IL-12 p40 subunit 
in common. Thus, the limitation of the IL-12 p40 expression in DCs treated with IFN-β may also 
reduce the amount of active IL-23 in the cytokine milieu (Yen et al., 2015; Huang et al., 2005; 
Huang et al., 2001; Nagai et al., 2003; McRae et al., 2000). In mice that lacked IFN-β 
expression, it was demonstrated that the IL-23 expression was significantly increased (Pennell et 
al., 2017). In addition, the treatment of mice DCs with IFN-β showed a decrease in IL-23 
production (Yen et al., 2015). Additionally, it was demonstrated that DCs throughout the 
lymphatic system had down-regulated IL-23 expression (Yen et al., 2015). Conflicting results 
exist for IFN-β effect on IL-23 p19 expression; some studies have shown that IFN-β treatment of 
DCs leads to modest increase in IL-23 p19 subunit expression, while other studies demonstrated 
that the IFN-β treatment of DCs leads to a drastic decrease in the IL-23 p19 subunit production 
(Yen et al., 2015; Nagai et al., 2003). These differences in IL-23 p19 expression in DCs treated 
with IFN-β may be the result varying exposure times to IFN-β (Nagai et al., 2003). The results of 
these various studies have shown that IFN-β treatment of DCs leads to the downregulation of IL-
23 expression throughout the lymphatic system. The reduction of IL-23 production could lead to 
the inability of CD4+ T cells to differentiate into TH17 cells. With reduced TH17 cell 
populations, the autoimmune response on myelin may not be as severe due to the decrease in the 
pro-inflammatory cytokines that TH17 cells produce.  
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 IL-27 is another cytokine of the IL-12 family. It has been found that the treatment of DCs 
with IFN-β led to the increase of IL-27 expression (Nagai et al., 2003). Additionally, the 
knockdown of endogenous IFN-β in mice showed marked decreases in the IL-27 concentration 
(Pennell et al., 2017). These changes in the expression of IL-27 by the treatment of DCs with 
IFN-β was suggested to be the effect of increased IL-27 p28 expression in DCs (Nagai et al., 
2003). Interestingly, IFN-β treatment led to no significant alterations to the EBI3 expression in 
DCs (Nagai et al., 2003). This result suggests that the IL-27 p28 subunit is a limiting factor for 
the expression of IL-27. These various studies showed that IL-27 expression is increased by IFN-
β treatment. IL-27 is known to induce proliferation of T cells, as well as increased IFN-γ when in 
the presence of IL-2 and/or IL-12 (Vignali et al., 2012). In MS immunopathology, the increased 
IL-27 may cause increased IFN-γ expression and increased TH1 cell differentiation (Parham, 
2015; Vignali et al., 2012). However, this hypothesis is only possible if both IL-12 and/or IL-2 
are present. It has been shown that IL-12 expression is limited in DCs which may lead to the 
ineffectiveness of IL-27 (Yen et al., 2015; Huang et al., 2005; Huang et al., 2001; Nagai et al., 
2003; McRae et al., 2000).  
 In all, the DC expression of IL-12 family cytokines (IL-12, IL-23, and IL-27) have been 
shown to be altered by IFN-β treatment. The IFN-β treatment reduces both IL-12 and IL-23 
expression in DCs by down-regulating the subunits of each cytokine (Yen et al., 2015; Huang et 
al., 2005; Huang et al., 2001; Nagai et al., 2003; McRae et al., 2000). The treatment of IFN-β 
also led to an increase in IL-27 production in DCs (Nagai et al., 2003; Pennell et al., 2017). In 
the case of MS, these cytokine changes limit the differentiation of CD4+ T cells into TH1 and 
TH17 cells. With reduced TH1 and TH17 cell populations, the inflammatory autoimmune response 
would be reduced (Parham, 2015). With a reduced inflammatory immune response, there would 
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be less demyelination in the CNS. Consequently, it could be hypothesized that the IFN-β 
treatment limits IL-12 family cytokines reducing the effector T cells that play a role in the 
process of demyelination.  
 
The Effect of IFN-β on the DC Expression of Cytokine IL-6: 
 IFN-β treatment of DCs has been found to produce increased expression of IL-6 (McRae 
et al., 2000; Pennell et al., 2017; Huang et al., 2005). IL-6 is a pro-inflammatory cytokine that 
plays a role in the differentiation of primed CD4+ T cells into TH17 cells (Parham, 2015). IL-6 is 
believed to function by increasing vascular permeability and metabolism of fat and muscle cells, 
subsequently altering body temperatures (Parham, 2015; Goldsby et al., 2002). Expression of IL-
6 may allow for increased permeability of immune cells through the blood-brain barrier (Parham, 
2015). In addition, the presence of IL-6 could suggest increases in the TH17 cell population that 
would lead to increased inflammatory response to myelin in the CNS (Parham, 2015; Goldsby et 
al., 2002).  
 DCs treated with IFN-β have shown varied effects in IL-6 cytokine expression. A murine 
model for MS has been used in many studies to evaluate the effect of IFN-β. The mice are 
induced with experimental autoimmune encephalomyelitis (EAE), which presents similar 
immunopathology and symptoms to MS (Pennell et al., 2017; Constantinescu et al., 2011). EAE 
is induced in the murine model by using T cells primed for distinct peptides in the myelin, such 
as myelin oligodendrocyte glycoprotein (Pennell et al., 2017). It has been shown that when 
endogenous IFN-β is knocked down in EAE induced mice, the expression of IL-6 was 
significantly increased in DCs (Pennell et al., 2017). In addition to the murine model, it has been 
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demonstrated that an increase in the IL-6 cytokine expression in human DCs occurred when IFN-
β treatment was used (Huang et al., 2005). These results support the positive effect of IFN-β on 
IL-6 expression. Thus, it may be suggested that the IFN-β treatment induces increased 
differentiation of TH17 cells, leading to a greater inflammatory autoimmune response to the 
myelin in the CNS of individuals with MS (Parham, 2015; Goldsby et al., 2002).  
 These increases in IL-6 cytokine expression may be linked to costimulatory molecule 
expression on DCs. It has been demonstrated that the CD40 receptor was upregulated on DCs 
following IFN-β treatment (Wiesemann et al., 2008; Marckmann et al., 2004). In addition, 
studies have found that the association of CD40 receptors with their ligand, found on T cells, led 
to the increase of IL-6 secretion in DCs (McRae et al., 2000). In cultures containing only DCs, 
the treatment of IFN-β led to no change in the expression of IL-6 (Mc Rae et al., 2000). These 
results have shown that IFN-β treatment may increase IL-6 concentration when in physiological 
conditions because DCs can associate with the CD40 ligand on T cells upregulating the IL-6 
expression in DCs (Wiesemann et al., 2008; Marckmann et al., 2004; McRae et al., 2000).  
 These results taken together have shown that IFN-β treatment of DCs led to the 
upregulation of IL-6 expression (McRae et al., 2000; Pennell et al., 2017; Huang et al., 2005). 
These results have also shown a novel mechanism for the increase of IL-6 expression in DCs 
following IFN-β treatment. The increase in CD40 receptor expression on DCs, caused by IFN-β 
treatment, suggests increased CD40 signaling which has been found to increase IL-6 expression 
in DCs (McRae et al., 2000; Pennell et al., 2017; Huang et al., 2005; Wiesemann et al., 2008; 
Marckmann et al., 2004). Consequently, IFN-β may function through an indirect pathway, 
namely, the CD40 pathway, to increase the IL-6 expression. This result may lead to increased 
differentiation of primed CD4+ T cells into TH17 cells and increases the vascular permeability to 
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immune cells (Parham, 2015; Goldsby et al., 2002). TH17 cells produce chemicals that are 
chemoattracts to neutrophils, which are phagocytic cells (Parham, 2015; Goldsby et al., 2002). In 
the case of MS, the blood-brain barrier is impaired and increased permeability occurs, such that 
neutrophils can enter the CNS and break down the myelin of individuals with MS (Prinz et al., 
2017).   
  
DCs Expression of IFN-γ and the Effect of IFN-β: 
 IFN-β treatment of DCs has been found to decrease the expression of IFN-γ (Pennell et 
al., 2017). IFN-γ functions by activating signaling in macrophages for pro-inflammatory 
cytokines (Parham, 2015; Goldsby et al., 2002). In addition to increasing macrophage cytokine 
expression, IFN-γ signaling in macrophages induces increased phagocytic activities (Parham, 
2015; Goldsby et al., 2002). IFN-γ is also known to increase the IL-12 cytokine expression in 
macrophages and natural killer cells (Parham, 2015; Goldsby et al., 2007). IFN-γ is one of the 
cytokines that differentiates primed CD4+ T cells into TH1 cells (Parham, 2015). In MS 
immunopathology, IFN-γ expression may lead to increased TH1 cell populations. Increased TH1 
cells could indicate increased macrophage activity and inflammatory response to myelin in the 
CNS (Parham, 2015; Goldsby et al., 2002).  
 IFN-β has been found to alter the expression of IFN-γ.  In a murine model induced with 
EAE and lacking IFN-β expression, the expression of IFN-γ was reduced (Yen et al., 2015). In a 
healthy murine model, the treatment of DCs with IFN-β on human DCs has been found to 
decrease the expression of IFN-γ (Huang et al., 2001). It has also been demonstrated that the 
treatment of IFN-β in the murine model led to an increase in IFN-γ expression in peripheral 
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blood mononuclear cells, which include DCs, throughout the lymphatic system (Ozenci et al., 
2000; Weyenbergh et al., 2000; Yen et al., 2015). Interestingly, there is a lack of data on the 
effects of IFN-β on human DCs. However, the studies on murine models have shown that IFN-β 
may have a direct effect on IFN-γ expression within DCs. The decrease to the expression of IFN-
γ expression may limit the differentiation of primed CD4+ T cells into TH1 cells, thus reducing 
the inflammatory response to myelin in the CNS of MS patients (Parham, 2015).  
 IFN-γ expression is known to be associated with IL-12 signaling. It has been 
demonstrated that IFN-β treatment of DCs decreases the subunits of IL-12 p35 and IL-12 p40 
that are necessary for the expression of IL-12 (Yen et al., 2015; Huang et al., 2005; Huang et al., 
2001; Nagai et al., 2003; McRae et al., 2000). One function of IL-12 is to induce expression of 
IFN-γ in immune cells (Vignali et al., 2012). Thus, the reduction of IL-12 expression in DCs by 
IFN-β could reduce the expression of IFN-γ in immune cells (Vignali et al., 2012). This result 
may lead to the reduction of TH1 cell populations. The reduction of TH1 cells could lead to 
reduced activation of macrophages and reduced production of pro-inflammatory cytokines. This 
series of events could reduce the inflammatory response enacted on myelin in the CNS in cases 
of MS.  
   
Effects of IFN-β on Effector CD4+ T cells: 
 In addition to affecting DC cytokine expression, IFN-β has been demonstrated to 
affect many different types of effector CD4+ T cells. In general, CD4+ T cells have been isolated 
from MS patients treated with IFN-β and non-treated patients. It was demonstrated that these 
cells were reactive to myelin basic protein by the increase of proliferation of CD4+ T cells from 
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non-treated patients in response to the presence of myelin basic protein (Bornsen, 2015). 
However, in the CD4+ cells isolated from IFN-β treated MS patients, a decrease in the 
proliferation of these CD4+ T cells was observed (Bornsen, 2015). This result was similarly 
shown in another study in which MS patients were treated with IFN-β and their CD4+ T cells 
were isolated (Hallal-Longo et al., 2007). These CD4+ T cells were found to have reduced 
reactivity to myelin basic protein, such that these CD4+ T cells had reduced proliferation in 
comparison to the non-treated control patients with MS (Hallal-Longo et al., 2007).   
TH1, TH17, and Treg cells have been shown to have altered cytokine and receptor 
expression and proliferation from IFN-β treatment (Boivin et al., 2015; Bornsen, 2015; Hallal-
Longo et al., 2015; Sweeney et al., 2011; Axtell et al., 2011; Tao et al., 2014; Zhang et al., 2011; 
Ramgolam et al., 2009). The alterations to these cells’ cytokine production and proliferation can 
present novel mechanisms for reducing the demyelination in MS patients. 
   
TH1 cells and The Effect of IFN-β Treatment: 
 TH1 cells are effector CD4+ T cells that function by producing IL-12 and IFN-γ and 
activating macrophages (Parham, 2015). These functions can increase the inflammatory response 
to myelin in patients with MS. IFN-β has been shown to decrease the proliferation of TH1 cells 
and decrease IFN-γ and other cytokine production by TH1 (Nagai et al., 2003; Boivin et al., 
2015; Bornsen, 2015; Hallal-Longo et al., 2015). The results of IFN-β treatment on TH1 cells 
may suggest a decrease in the growth of the TH1 cell population. The decrease in TH1 cell 
populations could indicate the reduction in macrophage activity, as well as reduced inflammatory 
response to myelin in the CNS. 
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 The generalized results of the effect of IFN-β treatment on MS patients CD4+ T cells are 
conserved in the TH1 cells. In a murine model induced with EAE, the TH1 cell proliferation was 
reduced by IFN-β on the mice (Bornsen, 2015). Studies have found that the treatment of murine 
TH1 cells in culture alone and in culture with DCs produced a decrease in the proliferation of the 
TH1 cells (Boivin et al., 2015). Interestingly, the study showed that the inhibition to TH1 cell 
proliferation was greater in the presence of DCs than in culture alone (Boivin et al., 2015). These 
results show that IFN-β treatment affects the populations of TH1 cells. In addition, the results 
may present a novel mechanism where the interaction between the antigen-presenting cells and 
CD4+ T cells is inhibited by some action of IFN-β. Taken together, these results show that TH1 
cells have reduced proliferation and replication from IFN-β that would affect the total population 
of TH1. A reduced population of TH1 cells may reduce the inflammatory response to MS and the 
macrophage activity in MS, thus suggesting a reduction in the demyelination of patients with 
MS.  
 IFN-β treatment on TH1 cells also causes alterations to cytokine expression.  It has been 
demonstrated that the treatment of TH1 cells with IFN-β in a murine model led to the decrease in 
the expression of IFN-γ and IL-2 (Boivin et al., 2015). In addition, it was shown that the 
treatment of human TH1 cells in culture with DCs with IFN-β had decreased IFN-γ and pro-
inflammatory cytokine tumor necrosis factor-α (TNF-α) (Nagai et al., 2003). It has also been 
found that IFN-β treatment on TH1 cells led to a decrease in the IL-12 p40 expression in these T 
cells (McRae et al., 1998). Interestingly, the cytokine expression of IL-10 in TH1 cells was 
increased following the treatment of TH1 cells with IFN-β (McRae et al., 1998). The reduction of 
IFN-γ and IL-12 p40 could reduce the differentiation of primed CD4+ T cells into TH1; thus, the 
IFN-β may reduce the autocrine signaling that occurs in T cells (Parham, 2015). The results also 
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showed a decrease of IL-2 cytokine expression from TH1 cells. IL-2 functions as a signaling 
molecule for proliferation in T cells (Parham, 2015). Thus, it can be hypothesized that the 
reduction of IL-2 cytokine expression in TH1 cells by IFN-β reduces TH1 cell proliferation. These 
results taken together suggest that IFN-β treatment acts on TH1 cells, reducing their cytokine 
expression and population growth. Interestingly, a decrease in TNF-α expression was seen 
following the IFN-β treatment of TH1 cells. The reduction in TNF-α could indicate decreased 
vascular permeability, thus limiting the movement of T cells and inflammatory cytokines into the 
CNS (Parham, 2015).  
 It has been demonstrated that IFN-β alters the expression of some receptors on TH1 cells 
that can be correlated to the alterations in proliferation and cytokine production. The treatment of 
murine TH1 cells with IFN-β led to the increase in the expression of PD-1 receptor on the surface 
of TH1 (Boivin et al., 2015). In addition, murine TH1 cells were shown to increase the expression 
of T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) (Boivin et al., 2015). TIM-3 
is known to be expressed in cases where T-cell exhaustion is present (Liu et al., 2018). The 
increased expression of TIM-3 and TIM-3 signaling has been found to reduce the expression of 
IFN-γ and TNF-α in effector T cells (Liu et al., 2018; Yang et al., 2008). The increase in the PD-
1 receptor could indicate increased PD-1 signaling in TH1. It has been shown that increased PD-1 
signaling in effector CD4+ T cells led to reductions in IL-2 and IFN-γ expression (Carter et al., 
2002; Schreiner et al., 2004; Goods et al., 2017; Latchman et al., 2001). In addition, the signaling 
through the TIM-3 receptor may suggest decreased IFN-γ and TNF-α from TH1 cells (Lieu et al., 
2018). These results taken together suggest that the reduction of cytokines may be the result of 
TIM-3 and PD-1 signaling. The changes in IL-2 and IFN-γ have been shown to reduce the 
proliferation and differentiation of TH1 cells. Thus, the TH1 cell population would be decreased 
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leading to reduced effector function from these cells and, by extension, reduced demyelination in 
patients with MS.  
IFN-β Treatment of TH17 and Its Effects: 
 IFN-β treatment on TH17 cells has been shown to affect their effector functions. TH17 
cells function by producing cytokines that attract neutrophils to the sites of infection (Parham, 
2015). In the case of MS, these cells may function by attracting the neutrophils to the blood-brain 
barrier and into the CNS where their phagocytic properties. In addition, TH17 cells produce many 
different pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-1β (Parham, 2015; Bettelli et 
al., 2008). These cytokines can increase vascular permeability, suggesting greater infiltration of 
immune cells and pro-inflammatory cytokines into the CNS (Parham, 2015). IFN-β treatment of 
TH17 cells has been shown to reduce the TH17 cell differentiation and proliferation and alter the 
cytokine expression of TH17 cells. These alterations to TH17 cells caused by IFN-β treatment 
may be indicative of novel mechanisms for the inhibition of TH17 cell function and TH17 cell 
population growth. In addition, the changes to TH17 cells may suggest reduced pro-inflammatory 
response in patients with MS and reduced immune cell movement into the CNS in patients with 
MS.  
  The treatment of IFN-β on TH17 cells may affect the TH17 population size. It has been 
observed that TH17 cells treated with IFN-β have reduced thymidine uptake (Sweeney et al., 
2011). In addition, it has been found that the treatment of IFN-β treatment on a murine model 
induced with EAE was shown to have reduced IL-17 producing CD4+ T cell density (Galligan et 
al., 2010). This reduction in TH17 population size could be the result of alterations to primed 
CD4+ T cell differentiation. TH17 cells are known to be differentiated by three cytokines: IL-6, 
IL-21, and IL-17 A and F (Parham, 2015; Bettelli et al., 2008). In general, it was demonstrated 
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that CD4+ T cells produced decreased IL-21 when treated with IFN-β (Tao et al., 2014). 
Specifically, in TH17 cells of a murine model, it was found that IFN-β treatment reduced the 
expression of both IL-17 A and IL-17 F in these T cells (Tao et al., 2014; Axtell et al., 2011; Tao 
et al., 2015; Zhang et al., 2011; Ramgolam et al., 2009). However, it is important to note that 
some discrepancy surrounds the effect of IFN-β on IL-17 A and F cytokines. Studies have found 
that the reductions in IL-17 A and F cytokine production in TH17 cells of mice required the 
presence of IFN-β and IFN-γ in culture (Axtell et al., 2011). In contrast other studies have shown 
that IFN-γ was not required to induce the changes in IL-17 A and F expression in TH17 (Tao et 
al., 2014; Rangolam et al., 2009; Zhang et al., 2011). Additionally, it has been demonstrated that 
the treatment of IFN-β on TH17 cells led to the downregulation of the TH17 cell transcription 
factor RORγT (Tao et al., 2014; Axtell et al., 2011). The downregulation of RORγT could be 
indicative of reduced IL-17 A and F expression and TH17 expansion. These results may suggest 
one hypothesis for the reduction in the TH17 cell density. The reduction in differentiating 
cytokines, namely, decreases in IL-21 and IL-17 A and F from IFN-β treatment on T cells, may 
cause reduced differentiation of TH17 cells which could explain the decrease in TH17 
proliferation and density. In the context of MS, the decreased TH17 populations could indicate 
decreased vascular permeability and inflammatory response, as well as reduced neutrophil 
response and attraction to the CNS, thus limiting the demyelination within the CNS. 
 Though inhibition of TH17 cells by IFN-β has been reported by many studies, it is 
important to note that key discrepancies exist in the overall effectiveness of IFN-β on TH17 cell 
populations. Most notably, it was previously described that upregulation of IL-6 cytokine 
expression in DCs was shown in the treatment of DCs with IFN-β (Pennell et al., 2017, Huang et 
al., 2005). It has been demonstrated that the IL-17 A decreased expression was mitigated only by 
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IFN-β’s and IFN-γ’s presence in culture with TH17 (Axtell et al., 2011). However, IL-17F was 
shown to be increased when TH17 cells were treated with IFN-β (Axtell et al., 2011). This 
finding was coupled with a result that showed mice induced with EAE had increased severity of 
EAE when TH17 cells were the primary effector T cell and IFN-β treatment occurred (Axtell et 
al., 2011). These results taken together suggest that IFN-β treatment increases TH17 cell 
expansion and cytokine production. In the context of MS, the findings hypothesize a possible 
mechanism in which IFN-β may not be an effective treatment in MS mediated primarily by TH17 
cells (Axtell et al., 2011). 
 
The Effects of IFN-β Treatment on Treg Cells: 
 IFN-β treatment has been found to increase the expansion of Treg cells and the expression 
of Treg cytokines. Treg cells function by producing anti-inflammatory cytokines that reduce the 
inflammatory response of effector T cells, such as TH1 and TH17 cells (Parham, 2015; Corthay, 
2009). Treg cells also act as suppressors of effector T cells by downregulating costimulatory 
molecules on antigen-presenting cells and reducing the concentration of IL-2 in the surrounding 
environment (Schmidt et al., 2012). These functions can reduce the populations of autoreactive 
TH1 and TH17 cells. This reduction could suggest a decrease in the demyelination of the CNS 
because the inflammatory response and phagocytic cell activation is reduced from the inhibitory 
effect on effector CD4+ T cells. In the context of MS, it has been found that MS patients Treg 
cells have reduced suppressive function in comparison to healthy controls (Venken et al., 2008). 
In addition, it was demonstrated that patients with MS have a lack of naïve CD4+ T cells with 
requisite markers for Treg differentiation (Haas et al., 2007). These findings coupled with the 
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presentation of increased Treg cell populations when MS patients are in relapse suggest the 
importance of Treg cells in the immunopathogenesis of MS (Dalla-Libera et al., 2011). 
 Treg cells have increased proliferation and differentiation when treated with IFN-β. The 
proliferation of Treg cells has been correlated to the signaling through the glucocorticoid-induced 
tumor necrosis factor receptor (GITR) found on the Treg cells (Cheng et al., 2015). It has been 
shown that the expression of GITR was increased in Treg cells following the treatment with IFN-
β (Cheng et al., 2015). In addition, it was demonstrated that the expression of the GITR ligand 
was upregulated on DCs by IFN-β treatment (Cheng et al., 2015). In MS patients treated with 
IFN-β, the percentage of Treg cells was increased in comparison to untreated MS patients 
(Korporal et al., 2008). These results taken together showed that the treatment of IFN-β on Treg 
cells led to increased Treg cell proliferation. The increase in Treg cell proliferation could indicate 
increased Treg cell population. With greater numbers of Treg cells, the increased Treg population 
could have greater suppressive effects of the Treg cells on effector T cells. In addition, there may 
be greater anti-inflammatory cytokines, such as IL-10, produced because there are greater 
numbers of Treg cells. 
 In the context of MS, the Treg cell suppressive function has been found to be reduced in 
patients with MS (Venken et al., 2008; Korporal et al., 2008). The suppressive functions of Treg 
cells are known to be related to the expression of the Treg transcription factor, FOXP3 (Fu et al., 
2004; Tai et al., 2012; Parham, 2015). Studies have found that FOXP3 is upregulated by the 
treatment of IFN-β on Treg cells (Venken et al., 2008; Cheng et al., 2015) It has been 
demonstrated that the suppressive functions of Treg cells were increased when MS patients were 
treated with IFN-β (Korporal et al., 2008). The increased suppressive function coupled with the 
increased Treg cell population could indicate a greater regulation of the autoreactive effector T 
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cells in MS. Greater regulation of these effector T cells would reduce the demyelination of the 
CNS of MS patients.   
The possible mechanisms of suppression from Treg cells involve CTLA-4 signaling.  The 
upregulation of FOXP3 transcription factor has been found to induce the expression of CTLA-4 
receptors on Treg cells (Cheng et al., 2015; Schreiner et al., 2004; Marckmann et al., 2008). 
CTLA-4 associates with CD80 and CD86 located on DCs (Parham, 2015; Schreiner et al., 2004; 
Marckmann et al., 2008). Both CD80 and CD86 were found to be upregulated by IFN-β 
treatment on DCs (Wiesemann et al., 2008; Marckmann et al., 2004). In addition, CTLA-4 has 
been shown to have a nearly 10-fold greater affinity for CD80 and CD86 in comparison to the 
CD28 receptor (Parham, 2015). These results have shown that IFN-β increased expression of 
FOXP3 that upregulates the expression of CTLA-4 (Cheng et al., 2015; Fu et al., 2004; Tai et al., 
2012). The upregulation of CTLA-4 coupled with its increased affinity for CD80 and CD86 may 
suggest a novel mechanism where naïve T cells cannot associate with the DCs and become 
activated. This result would increase the Treg cell population in comparison to other effector T 
cells. With reduced effector T cells, the demyelination of the CNS would be reduced.  
The signaling through the CTLA-4 has been shown to induce inhibitory pathways. 
CTLA-4 signaling was found to induce the expression of indolamine-2,3-dioxygenase in DCs 
(Fallarino et al., 2003). Indolamine-2,3-dioxygenase (IDO) functions by degrading tryptophan 
(Falllarino et al., 2003). It has been shown that IDO’s reduction of tryptophan led to the 
inhibition of T cell proliferation (Mellor et al., 2003; Fallarino et al., 2003). In the context of MS, 
the increase of Treg cells may increase the amount of CTLA-4 signaling in DCs. This increased 
signaling may induce an upregulation of IDO and increased IDO function. The effect of IDO has 
been shown to decrease the proliferation of T cells, such as the effector T cells. Reduced TH1 and 
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TH17 proliferation would reduce the demyelination within the CNS by diminishing the 
inflammatory response in the CNS.  
In addition to the receptor inhibitory mechanisms, Treg cells are known to produce anti-
inflammatory cytokines, such as IL-10 (Parham, 2015). The upregulation of FOXP3 and 
increased Treg cell population indicated that IL-10 was upregulated (Cheng et al., 2015; Parham, 
2015). The increased IL-10 cytokines have shown to reduce the activation of macrophages and 
limit the differentiation of TH17 and TH1 cells (Parham, 2015; Hsu et al., 2015; Goldsby et al., 
2002). The reduction of these effector T cells and the limitation to macrophage activation could 
indicate a decreased inflammatory response to the myelin in the CNS. This result would reduce 
the demyelination of the CNS in patients with MS.   
 
IFN-β Modulation of Immune Cell Transmigration: 
The movement of immune cells into the CNS is essential to the immunopathogenesis of 
MS. The immune cells are located within the lymphatic system and move into the CNS by a 
process called transmigration (Garg et al., 2015; Parham, 2015; Pinheiro et al., 2015). The CNS 
is protected by the blood-brain barrier (BBB) that is highly regulated controlling the amount of 
infiltrates into the CNS (Pinheiro et al., 2015). The BBB consists of three layers: the endothelial 
cells, the endothelial basement membrane, and the glial membrane (Pinheiro et al., 2015). The 
endothelial cells are connected by tight junctions that limit the movement of any vascular fluid or 
cells into the CNS (Pinheiro et al., 2015).  
The process of transmigration is one of great complexity. It involves three distinct 
phases: 1) attraction to the site of transmigration by chemokines, 2) adhesion of immune cell to 
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the endothelial cell, 3) production of matrix metalloproteinases (MMPs) to allow movement 
through the endothelial basement and glial membrane layers (Pinheiro et al., 2015; Parham, 
2015). The attraction of immune cells to the site of transmigration involves the presence of 
chemokines along the endothelial cell layer (Parham, 2015). Chemokines can be produced by 
many immune cells, including T cells, dendritic cells, macrophages, and neutrophils (Parham, 
2015). Immune cells express chemokine receptors which bind to the chemokines located on the 
endothelial barrier (Parham, 2015). The chemokines on the endothelial cell layer form a 
concentration gradient on the endothelial cells (Parham, 2015). This increased concentration on 
the endothelial cells attracts the immune cells expressing the chemokine receptor that associates 
with the chemokine present on the endothelial cells (Parham, 2015).  
The association with the chemokine by the immune cell involves a process by which the 
immune cell rolls along the endothelial cells (Parham, 2015). As the immune cell rolls, it 
associates with cell-adhesion molecules expressed on the endothelial cells (Parham, 2015). The 
cell-adhesion molecules that are present on the endothelial cells, include vascular cell-adhesion 
molecule 1 (VCAM-1), intercellular cell-adhesion molecule 1 (ICAM-1), P-selectin glycoprotein 
ligand 1 (PSGL-1) and intracellular cellular adhesion molecules 2 and 3 (Sagar et al., 2011). The 
association of these cell-adhesion molecules from the immune cell and the endothelial cell lead 
to the adherence of the immune cell to the endothelial cell layer (Parham, 2015). The association 
of the cell-adhesion molecules of the immune cell and the endothelial cell has been found to alter 
the tight junctions leading to the movement of the immune cell through the endothelial cell layer, 
which is also called diapedesis (Parham, 2015; Pinheiro et al., 2015).The final phase of the 
transmigration process that is specific to the movement through the BBB is the expression of 
MMPs (Pinheiro et al., 2015). Many different MMPs can be expressed by immune cells, but their 
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function is redundant. MMPs function by cleaving the glial and endothelial basement layer 
(Pinheiro et al., 2015). This function allows for the immune cell to move into the CNS.    
 IFN-β has been found to alter the chemokine and chemokine receptor expression, cell-
adhesion molecule expression, and MMP expression of DCs and CD4+ T cells. These changes to 
the different components of the transmigration process by IFN-β may suggest novel mechanisms 
that reduce the movement of DCs and CD4+ T cells into the CNS. In the context of MS, this 
reduced movement could indicate decreased inflammatory response to myelin and immune cell 
attack and function within the CNS.     
  
Interferon-β and Dendritic Cell Transmigration: 
 Dendritic cells are known to migrate through many tissues of the body carrying antigens 
to the lymphatic system from the site of antigen. In the context of MS, the antigens are auto-
antigens, such as MOG or MBP (Peschl et al., 2017; Beniac et al., 1997). It has been 
demonstrated in a murine model of EAE that the increased movement of DCs into the CNS was 
linked to the increased severity of EAE (Sagar et al., 2012). IFN-β treatment of DCs has been 
shown to cause changes to chemokine receptor expression, cell-adhesion molecule expression, 
and MMP expression by DCs.  
 IFN-β treatment plays a role in the alteration of DCs expression of chemokines and 
chemokine receptors. DCs have been found to express chemokine receptors CXCR5, CXCR4, 
CCR4, and CCR7 (Sallusto et al., 1999). The treatment of IFN-β in vivo in mice and in vitro on 
human DCs have shown a down-regulation of CCR7 expression in DCs (Yen et al., 2010; 
Pennell et al., 2017). The CCR7 receptor attaches to chemokines CCL21 and CCL19 (Parham, 
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2015). These chemokines attract DCs to lymph nodes where they can prime T cells for attack 
against the myelin (Parham, 2015). The chemokines can also attract the DCs to the BBB, 
allowing for their phagocytosis and processing of auto-antigens for presentation in MHC 
molecules (Parham, 2015). The decrease to the expression of CCR7 on DCs could indicate the 
decreased chemotaxis of DCs to and from the lymph nodes and the CNS. This reduced 
chemotaxis may suggest reduced movement of DCs into the CNS, thus limiting the presentation 
of auto-antigens to T cells and the priming of autoreactive T cells.  
 In addition to the reduction of CCR7 expression in DCs, IFN-β treatment has been shown 
to affect the expression of cell-adhesion molecules in DCs. Various cell-adhesion molecules 
have been found to play a role in the adhesion of DCs to endothelial cells, including very-late 
antigen 4 (VLA-4), lymphocyte function associated antigen 1 (LFA-1) P or E selectin, and 
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DCSIGN) (Sagar 
et al., 2011). Studies have shown that the blockage of expression of VCAM-1, ICAM-1, and 
ICAM-2 limited the adhesion of DCs to human micro-vessel endothelial cells (Arjmandi et al., 
2009). IFN-β has been shown to indirectly affect the expression of the cell-adhesion molecules 
on endothelial cells. For example, the downregulation of pro-inflammatory cytokines TNF-α and 
IL-1β has been found to reduce the expression of VCAM-1, ICAM-1, and P- and E-selectin in 
endothelial cells (Raab et al., 2002). IFN-β treatment on naïve CD4+ T cells and effector CD4+ 
T cells has demonstrated that IL-17 cytokine expression was decreased (Tao et al., 2014; Axtell 
et al., 2011; Tao et al., 2015; Zhang et al., 2011; Ramgolam et al., 2009). It has been found that 
reductions to IL-17 signaling decreases TNF-α and IL-1β expression (Bettelli et al., 2008). In 
addition, IFN-γ signaling in endothelial cells has been correlated with increases in the expression 
of ICAM-1 in endothelial cells (Chen et al., 2001; Raab et al., 2002). Studies have shown that the 
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treatment of IFN-β on DCs reduced the expression of IFN-γ in DCs (Nagai et al., 2003; Yen et 
al., 2015).  The reduction of IFN-γ production may suggest a down-regulation of ICAM-1 on 
endothelial cells. These results taken together suggest indirect inhibition of cell-adhesion 
molecule expression on endothelial cells by IFN-β treatment. The reduction of endothelial cells 
by IFN-β would decrease the adhesion of DCs to the endothelial cells, and, thus, reduce the 
transmigration of DCs into the CNS or lymph nodes. 
 IFN-β treatment has been demonstrated to reduce the permeability of a bovine endothelial 
cell layer in inflammatory conditions that induce increased permeability (Kraus et al., 2008). 
Many possible hypotheses exist for this reduced permeability of the endothelial cell layer. One 
such hypothesis involves ICAM-1 signaling. Cell-adhesion molecules have been found to play a 
role in the alterations of tight junctions between endothelial cells. The adhesion of immune cells 
to the endothelial cell layer led to a distinct arrangement ICAM-1 along the endothelial cell 
membrane (Pinheiro et al., 2015; Greenwood et al., 2011). The arrangement of ICAM-1 caused 
distinct ICAM-1 signaling that induces changes to the tight junctions of endothelial cells, thus 
allowing the immune cell to move through (Pinheiro et al., 2015; Greenwood et al., 2011). The 
decreased expression of pro-inflammatory cytokines TNF-α, IL-1β, and IFN-γ as an effect of 
IFN-β have been shown to limit the expression of ICAM-1 in endothelial cells (Raab et al., 2002; 
Chen et al., 2001). Interestingly, ICAM-1 on the endothelial cell associates with LFA-1 on the 
DC (Parham, 2015; Sagar et al., 2011). LFA-1 expression on leukocytes was reported to be 
down-regulated in MS patients that underwent IFN-β treatment (Muraro et al., 2004). The 
reductions to ICAM-1 and LFA-1 may limit the movement of immune cells, such as DCs, 
through tight junctions by down-regulating ICAM-1 signaling.  
Young 43 
 
 Another possible hypothesis for the decreased permeability of the endothelial cell layer in 
inflammatory conditions involves the cell-adhesion molecules and their associations with tight 
junctions. Tight junctions consist of interlocking proteins, such as junctional adhesion molecule 
A (JAM-A) and platelet endothelial cell-adhesion molecule (PECAM) (Saga et al., 2011). 
Studies found that the cell-adhesion molecule LFA-1 has affinity for the JAM-A tight junction 
protein (Wojcikiewics et al., 2009). The association of LFA-1 present on DCs may disrupt the 
tight junction association of JAM-A and another cell-adhesion molecule, thus allowing for a 
decrease in the stability of the tight junction. LFA-1 expression on leukocytes, which include 
DCs and CD4+ cells, was shown to be reduced in MS patients receiving IFN-β treatment 
(Muraro et al., 2004). With reduced LFA-1 expression on DCs, the immune cell movement 
through the endothelial cell layer may be inhibited because there is less disruption of the tight 
junctions.  
 The final phase of transmigration involves breakdown of the glial and endothelial 
basement membrane layer by MMPs (Pinheiro et al., 2015). IFN-β treatment of DCs has been 
shown to alter the expression of MMPs by DCs both directly and indirectly. DCs produce MMP-
9, MMP-12, and MMP2 (Toth et al., 2013; Zozulya et al., 2007). The exposure of DCs to 
inflammatory conditions in which prostaglandin E2 (PGE2), TNF-α, IL-1β, and granulocyte-
macrophage colony-stimulating factor (GMCSF) are present led to the upregulation of MMP-12 
and MMP-9 (Toth et al., 2013). The production of IL-17 has been found to induce the expression 
of PGE2, TNF-α, and IL-1β in immune cells (Fossiez et al., 1996). IFN-β treatment has been 
demonstrated to reduce the expression of IL-17 by immune cells (Tao et al., 2014; Axtell et al., 
2011; Tao et al., 2015; Zhang et al., 2011; Ramgolam et al., 2009). In addition, IFN-β treatment 
on DCs led to the decrease of MMP-9 expression by DCs (Yen et al., 2010; Toth et al., 2013). 
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These results together showed that MMPs were down-regulated by the treatment of IFN-β. The 
inhibition of inflammatory cytokines by down-regulation of IL-17 expression could indicate the 
reduced production of MMP-9 and MMP-12 by DCs. This indirect inhibition coupled with the 
direct effect of IFN-β on DCs to down-regulate MMP-9 may suggest reduced ability of DCs to 
breakdown the glial and endothelial basement membrane layers of the BBB. This decrease in 
transmigration function may hinder the DCs entrance into the CNS. The decrease of DCs within 
the CNS may reduce the severity of MS.   
  
The Effect of Interferon-β on T Cell Transmigration:   
 T cells transmigrate through the same process as DCs. However, differences in cell type 
lead to differences in the chemokine receptor, chemokines, and MMPs produced. In a murine 
model of MS, reduced T cell transmigration was shown following IFN-β treatment (Chen et al., 
2015). T cells express many different chemokine receptors that associate with many different 
chemokines (Parham, 2015; Cheng et al., 2015). The effects of IFN-β on cell-adhesion molecules 
and MMPs in T cells may suggest hypotheses as to why T cell transmigration is altered  
 It is important to note that IFN-β treatment has been shown to affect both chemokines 
and chemokine receptors. For example, in MS patients that are untreated, the expression of 
chemokine receptors CCR4, CCR5, and CCR7 are down-regulated (Krakauer et al., 2006; Cheng 
et al., 2015). Following treatment with IFN-β, the expression of these chemokine receptors was 
increased in the CD4+ T cells of these patients (Krakauer et al., 2006). In contrast, the expression 
of the chemokine receptor CXCR3 that is highly expressed on TH1 cells was decreased by IFN-β 
treatment (Sorensen et al., 2002; Groom et al., 2011). For chemokines, MS patients treated with 
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IFN-β showed increased expression of many chemokines including CCL1, CCL2, CCL7, 
CXCL9, CXCL10, CXCL11, and CXCL12 in CD4+ T cells (Cepok et al., 2009). However, 
studies have found that IFN-β treatment in patients with MS reduced the expression of 
chemokines, such as CCL3, CCL5, and CXCL10 (Cheng et al., 2015). In all, these results have 
shown conflicting findings. These findings suggest that a better understanding of the chemokine 
receptors and chemokines in CD4+ T cells may be necessary the understand IFN-β’s effect. 
  CD4+ T cells are known to express various cytokines that can be affected by IFN-β 
treatment. TH1 cells have decreased expression of IFN-γ following IFN-β treatment (Boivin et 
al., 2015; Nagai et al., 2003). TH17 cells, when treated with IFN-β, were shown to have reduced 
expression of IL-17 cytokines (Tao et al., 2014; Axtell et al., 2011; Tao et al., 2015; Zhang et al., 
2011; Ramgolam et al., 2009). The reduction to IFN-γ and IL-17 has been found to reduce the 
cell-adhesion molecules ICAM-1, VCAM-1, and P- and E-selectin by reducing the pro-
inflammatory cytokine expression (Raab et al., 2002; Chen et al., 2001). The reduction in the 
cell-adhesion molecules present on the endothelium could suggest reduced adherence of CD4+ T 
cells on the endothelial cell layer. CD4+ T cells are also known to express the LFA-1 cell-
adhesion molecule similar to DCs (Parham, 2015; Pinheiro et al., 2015). Similar to the 
hypotheses found in DC transmigration studies, the LFA-1 molecules have been shown to be 
reduced in expression MS patient leukocytes treated with IFN-β (Muraro et al., 2004). The 
reduction of LFA-1 cell-adhesion molecules in CD4+ T cells could suggest that tight junctions 
would not be disrupted, leading to decreased transmigration of CD4+ T cells into the CNS. 
CD4+ T cell expression of MMPs has been shown to be affected by IFN-β treatment. In 
cases of MS, it has been demonstrated that MS patients have increased ratios between MMPs and 
tissue inhibitor of metalloproteinases (TIMPs) (Avolio et al., 2005). When these ratios are 
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increased, there is an increased movement of immune cells through the cell layers (Avoloi et al., 
2005). Studies have shown that there is variation between the cell types for the MMPs produced. 
In the case of TH1 cells, high levels of MMP2 and MMP9 have been reported, whereas in TH17 
cells, MMP3 and MMP13 was found to be highly expressed (Ovieda-Orta et al., 2008; Park et 
al., 2005). IFN-β treatment in MS patients has been shown to reduce the expression of MMP-8 
and MMP-9 in the blood serum of MS patients (Alexander et al., 2010). Additionally, studies 
have reported that the treatment of IFN-β in MS patients reduced their MMP to TIMP ratio by 
increasing TIMP-1 and decreasing MMP-9 (Avolio et al., 2005). These results taken together 
suggest that IFN-β may reduce MMP function by increasing its inhibitor (TIMP). Additionally, 
IFN-β treatment has been shown to reduce MMPs directly, thus decreasing the ability of T cells 
to transmigrate into the CNS.  
  
Concluding Remarks: 
 The role of IFN-β in the treatment of MS is one of increasing complexity. Studies have 
reported that IFN-β can affect multiple cell types that are involved in the complex 
immunopathogenesis of MS. In general, IFN-β treatment has been shown to reduce the 
inflammatory response by limiting the pro-inflammatory cytokine production by effector CD4+ 
T cells and DCs. In addition, IFN-β treatment has been correlated to a shift of cytokines from 
pro-inflammatory cytokines, such as IL-17, IFN-γ, IL-12, and TNF-α, to anti-inflammatory 
cytokines, such as IL-10 and IL-27. The shift from pro-inflammatory cytokines to anti-
inflammatory cytokines has been shown to reduce the cell populations of TH1 and TH17 cells. 
Additionally, IFN-β treatment has been shown to inhibit TH1 and TH17 cell proliferation. These 
shifts in the cytokine profile have also been shown to induce the growth of Treg cell populations. 
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Overall, these shifts in cytokine production may induce greater regulation of autoreactive 
effector T cells and reduce the progression of MS by limiting the effector T cell functions and 
population growth. In addition, these cytokines have been found to affect the expression of cell-
adhesion molecules on endothelial cells inhibiting the movement of immune cells. IFN-β 
treatment has also been found to reduce some cell-adhesion molecules on leukocytes. In total, 
IFN-β treatment in MS patients suggests a complex system where pro-inflammatory response to 
myelin is reduced by changing the expression of cytokines, receptors, and cell-adhesion 
molecules effector CD4+ T cells and DCs (Table 1.). 
 The many effects of IFN-β on effector CD4+ T cells and DCs have shown to alter the 
protein expression of these immune cells. These alterations have been suggested to be used as 
measurements of effectiveness in MS patients receiving IFN-β. For example, the upregulation of 
CD80 and CD86 molecules on DCs has been suggested to be used as a measure of IFN-β 
treatment effectiveness (Wiesemann et al., 2008; Marckmann et al., 2004). This measurement of 
effectiveness could show earlier effectiveness of IFN-β treatment in MS patients. Another 
example is that in the murine model of EAE induced by TH17 cells, IFN-β treatment was shown 
to exacerbate the symptoms in mice (Axtell et al., 2011). Reduced effectiveness of IFN-β 
treatment in MS patients presenting with an high TH17 cell population may allow for better 
treatment options to be given to MS patients with high TH17 populations; thus giving a marker 
for proper IFN-β treatment in MS patients (Axtell et al., 2011). The analysis of IFN-β’s roles in 
the treatment of MS and its effects on immune cells provides better understanding to the cases of 
MS where IFN-β treatment is most beneficial for the patient.      
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